Persistent acantholytic dermatosis

Dodd, Harold; Sárkány, I.

doi:10.1111/j.1365-2230.1984.tb00832.x

Cited by 10 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25,26 The literature contains many examples of retinoid use that testifies to its presumed effectiveness. Double-blind trials have not been performed with either these drugs or with vitamin A.…”

Section: Treatmentmentioning

confidence: 99%

Grover's disease: 34 years on

Quirk

Heenan

2004

Aust J Dermatology

View full text Add to dashboard Cite

Grover's disease is an entity reported worldwide and recognized as a common disease since Grover first described it in 1970. Its cause remains obscure, but hospitalized, febrile and sun-damaged patients are particularly prone. It is frequently associated with some other skin diseases, including eczemas, psoriasis and solar keratoses. Acantholysis is the universal histological finding in all the varying clinical presentations. Treatment in the past has been ad hoc, but topical therapy, acitretin and phototherapy can suppress symptoms.

show abstract

Section: Treatmentmentioning

confidence: 99%

Grover's disease: 34 years on

Quirk

Heenan

2004

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…Concerning its mechanism of action, etretinate inhibits the migration of neutrophilic and eo sinophilic granulocytes by a direct effect on cell motility [10], probably by changing the cells' capability to respond to chemoattrac tants or by modulating components of the epidermis or basal membrane zone to act as chemoattractants. These explanations may be a basis for the effectiveness of etretinate in treating pemphigus herpetifor mis [11,12], pemphigus vegetans, [13] the type of bullous pemphigoid with strong eo sinophilic infiltrate [3] of Grover's disease [14] and erythema an nulare centrifugum, i.p. cum pustulatione [15].…”

Section: Etretinatementioning

confidence: 99%

New Indications and New Retinoids

Gollnick¹

1987

Dermatology

View full text Add to dashboard Cite

In addition to well-accepted indications, etretinate has a beneficial effect in a variety of other dermatoses such as the hyperkeratotic eczema of the palms and soles, prurigo nodularis, and other nonpsoriatic, sterile, pustular eruptions. Due to its influence on dermal inflammatory processes and immunomodulation of the tissue response, etretinate is effective in cutaneous lupus erythematosus, certain bullous disorders like pemphigus herpetiformis, the persistent variant of Grover’s disease, dermatitis herpetiformis, and bullous pemphigoid. Isotretinoin is reported to be effective in cutaneous sarcoidosis, disseminated granuloma annulare, systemic sclerosis and tumors of the cutaneous appendages. New synthetic retinoids have been developed. Etretin, the main metabolite of etretinate, was shown to be effective and to have a short elimination half-life of – 50 h. Arotinoid ethyl ester and arotinoid-free carboxylic acid are effective in minimal doses 500-fold lower than etretinate. Arotinoid ethyl ester was shown not to increase serum lipids. Arotinoid ethyl sulfone is the first retinoid without bone toxicity in animal experiments. Motretinide is the ethylamide of tretinoin and is reported to be effective in the local treatment of acne. Some of the new poly-aromatic retinoids appear to have sebosuppressive, antikeratinizing and/or anti-inflammatory effects via topical application.

show abstract

“…Oral administration of etretinate (0.25-0.50mg/kg/day), representative of the second retinoid generation and parent compound of acitretin, to two patients with persistent GD resulted in a distinct improvement of the skin lesions within 6 weeks of treatment [25]. Also, Dodd and Sarkany (1984), [26] reported a clinical improvement of a patient with persistent GD after treatment with oral etretinate (50mg/day) over an unknown period of time. Mokni et al (1993), [27] reported a patient with persistent acantholytic dermatosis (possibly GD) who revealed an 80% remission of his lesions after 6 months of therapy with oral acitretin (0.50mg/kg/day).…”

Section: Case Discussionmentioning

confidence: 99%